|
시장보고서
상품코드
1877473
세계의 혈액응고장애 시장 : 유형별, 치료법별, 검사법별, 최종사용자별, 국가별, 지역별, 산업 분석, 규모, 점유율, 예측(2025-2032년)Coagulation Disorders Market, By Type, By Treatment, By Test, By End Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032 |
||||||
혈액응고장애 시장 규모는 2024년 105억 6,789만 달러로 평가되었고, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 6.8%로 성장할 전망입니다.
혈액응고장애 시장은 출혈성 질환 및 응고장애의 유병률 증가뿐만 아니라 유전자 치료 및 재조합 응고 인자 등의 맞춤형 의료의 진보에 의해 견인되고 있습니다. 진단 및 관리에 대한 AI 통합은 예측 분석과 개별화된 모니터링을 통해 치료 계획을 최적화하고 예측 기간 동안 시장에서 수익성 있는 기회를 창출할 것으로 기대됩니다. 또한 디지털 건강 솔루션은 원격 모니터링과 텔레메디신 상담을 촉진하여 환자의 편의성 향상, 치료 준수율 개선, 치료 성과 향상에 기여하고 있습니다. 그러나 공급망의 혼란과 건강 관리 인프라의 지역 격차가 시장 확대의 과제가 되고 있습니다. 또한 치료비 상승, 규제 과제, 신규 검사 기술의 보급 지연 등 시장 성장을 억제하는 요인입니다.
혈액응고장애 시장 역학
유전자 치료 및 맞춤형 의료 도입 확대
혈우병 및 기타 희귀한 출혈성 질환은 전통적으로 재조합 또는 혈장 유래의 응고 인자를 반복적으로 투여해야 했습니다. 그러나 이러한 치료법은 비용이 많이 들고 평생 치료를 필요로 하고 억제제 발생 위험을 수반합니다. 유전자 치료는 현재 결핍된 유전자의 기능적 사본을 삽입함으로써 응고 인자 결핍을 한 번의 치료로 장기적으로 개선할 가능성을 제공합니다. 예를 들어, 2023년 6월에 미국 식품의약국(FDA)은 혈우병 A에 대한 록타비안(바이오마린사)과 혈우병 B에 대한 헴제닉스(CSL 베링/유니큐어사)와 같은 유전자 치료를 승인했습니다. 혈우병 A는 응고 인자 VIII(FVIII)의 결핍을 특징으로 하는 희귀 유전성 질환으로, 출혈 시간의 연장을 일으키고 통제 불가능한 내출혈 및 관절 손상과 같은 생명을 위협하는 합병증을 유발할 수 있습니다. 또한, 개인화된 의료는 이러한 변화를 보완하고 개인의 유전자 프로파일을 기반으로 치료 계획을 수립함으로써 치료의 정밀한 표적화와 부작용을 최소화합니다. 유전자 검사 및 차세대 시퀀싱(NGS)을 포함한 분자진단 기술의 진보는 조기 진단과 환자의 층별화를 촉진하고 환자 고유의 특성에 가장 적합한 치료법을 결합하여 치료 성과를 향상시킵니다.
혈액응고장애 시장 : 세분화 분석
세계의 혈액응고장애 시장은 유형, 치료, 검사, 최종 사용자 및 지역에 따라 세분화됩니다.
유형별로는 혈우병 A, 혈우병 B, 폰 빌레브랜드병, 인자 VIII, 인자 V 인자, 인자 X 인자, 인자 XII 결핍증 등 5가지 범주로 분류됩니다. 혈우병 A는 응고 인자 VIII의 결핍을 특징으로 하는 유전성 질환이며, 혈우병 B는 인자 IX의 결핍을 동반하여 유사한 증상을 나타냅니다. 폰 빌레브랜드 병은 폰 빌레브랜드 인자의 낮은 값 또는 결핍으로 인한 혈액 응고에 영향을 미치고 점막 출혈을 유발합니다. 인자 II, 인자 V, 인자 X, 인자 XII 결핍은 다른 응고 인자가 관여하는 드문 혈액응고장애이며 다양한 출혈 증상을 유발합니다.
치료법에 근거한 시장 내역은 다음 3가지입니다. 철분 보충 요법, 수혈 요법 등. 철분 보충 요법은 만성 실혈과 관련된 빈혈을 개선하는 데 사용됩니다. 한편, 수혈 요법은 잃어버린 혈액을 보충하고 응고 인자의 회복을 촉진합니다. 요인 보충 요법, 데스모프레신, 응혈괴 보존제, 유전자 요법, 비 요인 요법은 질병의 유형과 중증도에 따라 치료법을 조정합니다.
혈액응고장애 시장 - 지역별 분석
혈액응고장애 시장은 의료 인프라, 질병 유병률 및 지역 투자에 의해 형성되는 명확한 지리적 동향을 보여줍니다. 북미는 혈액응고장애의 높은 유병률, 확립된 헬스케어 시스템, 활발한 연구개발로 시장을 독점하고 있습니다. 또한 혈장 채취 센터에 대한 투자 증가는 시장 성장을 더욱 촉진하고 있습니다. 유럽은 2위 점유율을 차지하고 독일, 영국, 프랑스, 이탈리아, 스페인 등의 국가들이 크게 공헌하고 있습니다. 이 지역은 광범위한 조사 협력, 규제 당국의 승인, 높은 환자 의식을 통해 성장을 볼 수 있습니다. 고령화와 진단 능력의 발전은 혈액응고장애 관리에 대한 수요 증가에 기여합니다. 아시아태평양은 가장 빠르게 성장하고 있으며, 중국, 인도, 일본의 의료비 지출 증가, 급속한 도시화, 의료 인프라의 확충이 성장의 원동력이 되고 있습니다. 한편, 중동, 아프리카, 라틴아메리카 등의 지역에서는 의료에 대한 액세스 제한이나 인지도가 낮기 때문에 성장이 완만합니다. 그러나 이러한 지역에서도 의료 진보와 국제 협력이 진행되고 있기 때문에 매우 큰 잠재적 가능성을 가지고 있습니다.
혈액응고장애 시장 : 경쟁 구도
혈액응고장애 시장 경쟁 구도은 첨단 치료법 및 진단 솔루션을 통해 혁신을 추진하는 여러 주요 세계 기업의 존재를 특징으로 합니다. 주요 시장 기업은 환자의 치료 성과와 삶의 질을 향상시키기 위해 유전자 치료, 장시간 작용 재조합 응고 인자, 단일클론항체, 바이오시밀러 등의 혁신적인 치료 옵션의 개발에 주력하고 있습니다. 예를 들어, 2024년 4월에 헤모네틱스가 TEG 6s 지혈 분석 시스템을 위한 'Global Hemostasis-HN 분석 카트리지'에 대해 미국 식품의약국(FDA)으로부터 510(k) 인가를 취득했다고 발표했습니다. 이 새로운 카트리지는 TEG 6s 시스템의 점탄성 검사 기능을 확장하여 성인 심장혈관 수술과 간 이식을 받는 완전 헤파린화 환자에게도 대응할 수 있게 되었습니다. 또한 혈장이 없는 재조합 제품의 채택과 CRISPR과 같은 유전자 편집 기술의 진보도 경쟁을 형성하는 중요한 동향입니다. 각 회사는 또한 PoC 진단 도구 및 웨어러블 응고 모니터링 장치에 대한 투자를 추진하고 있으며, 개인화되고 편리한 환자 관리로의 전환을 촉진하고 있습니다. 제품 포트폴리오와 지역적 존재의 확대를 도모하면서 전략적 제휴, 합병, 인수가 자주 이루어지고 있습니다.
목차
제1장 혈액 응고 장해 시장 개요
- 분석 범위
- 시장 추정 기간
제2장 주요 요약
- 시장 분석
- 경쟁 인사이트
제3장 혈액응고장애의 주요 시장 동향
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 시장 전망 동향
제4장 혈액응고장애 시장 : 산업 분석
- PEST 분석
- Porter's Five Forces 분석
- 시장 성장 전망 : 매핑
- 규제 체제의 분석
제5장 혈액응고장애 시장 : 높아지는 지정학적 긴장의 영향
- COVID-19 팬데믹의 영향
- 러시아·우크라이나 전쟁의 영향
- 중동 분쟁의 영향
제6장 혈액응고장애 시장 정세
- 혈액응고장애 시장 점유율 분석(2024년)
- 주요 제조업체별 분석 데이터
- 기존 기업의 분석
- 신규 기업의 분석
제7장 혈액응고장애 시장 : 유형별
- 개요
- 부문별 점유율 분석 : 유형별
- 혈우병 A
- 혈우병 B
- 폰 빌레브란트병(Von Willebrand's Disease)
- 제II인자·제V인자·제X인자·제XII인자 결핍증
- 기타
제8장 혈액응고장애 시장 : 치료법별
- 개요
- 부문별 점유율 분석 : 치료법별
- 철분 보급 요법
- 수혈 요법
- 기타
제9장 혈액응고장애 시장 : 검사법별
- 개요
- 부문별 점유율 분석 : 검사법별
- 전혈구수(CBC)
- 혈소판 응집 검사
- 피브리노겐 분석
- 프로트롬빈 시간 검사
- 기타
제10장 혈액응고장애 시장 : 최종 사용자별
- 개요
- 부문별 점유율 분석 : 최종 사용자별
- 병원
- 전문 클리닉
- 진단센터
- 혈액은행
- 기타
제11장 혈액응고장애 시장 : 지역별
- 소개
- 북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
- 유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
- 아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
- 라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
- 중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타
제12장 주요 벤더 분석 : 혈액응고장애업계
- 경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
- 기업 프로파일
- Griflos SA
- Hoffman-La Roche Ltd
- Bio-Rad Laboratories
- B Braun
- Abbott
- Bayer AG
- Helena Laboratories
- Fresenius Kabi
- Haemonetics Corporation
- VarmX BV
- Biogen Inc.
- Others
제13장 AnalystView의 전방위 분석
SHW 25.12.23Coagulation Disorders Market size was valued at US$ 10,567.89 Million in 2024, expanding at a CAGR of 6.8% from 2025 to 2032.
The coagulation disorders market is driven by increasing prevalence of bleeding and clotting disorders and advances in personalized medicine such as gene therapies and recombinant clotting factors. Integration of AI in diagnostics and management optimizes treatment plans through predictive analytics and individualized monitoring is expected to generate lucrative opportunities in the market over forecast period. Additionally, digital health solutions are increasing patient convenience, improving adherence, and enhancing outcomes by facilitating remote monitoring and telemedicine consultations. However, supply chain disruptions and geographic disparities in healthcare infrastructure pose challenges to market expansion. Moreover, high treatment costs, regulatory challenges, and slower adoption of novel testing technologies are also restraining the market growth.
Coagulation Disorders Market- Market Dynamics
Rising Adoption of Gene Therapies and Personalized Medicine
Hemophilia and other rare bleeding disorders have historically required repeated infusions of recombinant or plasma-derived clotting factors. Nevertheless, these treatments are expensive, need lifelong care, and carry a risk of inhibitor development. Gene therapies now offer the potential for one-time, long-lasting correction of coagulation factor deficiencies by inserting functional copies of defective genes. For instance, in June 2023, U.S. FDA have approved gene therapies such as Roctavian (BioMarin) for Hemophilia A and Hemgenix (CSL Behring/UniQure) for Hemophilia B. Hemophilia A is a rare genetic disorder characterized by a deficiency of clotting factor VIII (FVIII), which leads to prolonged bleeding and may cause life-threatening complications such as uncontrolled internal bleeding and joint damage. Additionally, personalized medicine further complements this shift by tailoring treatment plans based on individual genetic profiles, enabling precise targeting of therapy and minimizing adverse effects. Advances in molecular diagnostics, including genetic testing and next-generation sequencing (NGS), facilitate early diagnosis and patient stratification, which enhances outcomes by matching the most appropriate therapies to patient-specific characteristics.
Coagulation Disorders Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.8% over the forecast period (2025-2032)
Based on Type segmentation, Hemophilia A is predicted to show maximum market share in the year 2024
Based on Treatment segmentation, Blood Transfusion is the leading Treatment in 2024
Based on Test segmentation, Prothrombin Time Test is the leading Test in 2024
Based on End Users segmentation, Hospitals is the leading End Users in 2024
On the basis of region, Asia Pacific is the leading revenue generator in 2024
Coagulation Disorders Market- Segmentation Analysis:
The Global Coagulation Disorders Market is segmented on the basis of Type, Treatment, Test, End Users, and Region.
The market is divided into five categories based on Type: Hemophilia A, Hemophilia B, Von Willebrand's Disease, Factor II, V, X, XII Deficiencies, and Others. Hemophilia A is a genetic disorder characterized by a deficiency of clotting factor VIII, while Hemophilia B involves a deficiency of factor IX with similar symptoms. Von Willebrand's Disease results from low or defective von Willebrand factor, affecting blood clotting and causing mucosal bleeding. Factor II, V, X, XII deficiencies are rare coagulation disorders involving other clotting factors, leading to variable bleeding symptoms.
The market is divided into three categories based on Treatment: Iron Supplementation, Blood Transfusion, and Others. Iron supplementation is used to address anemia related to chronic blood loss. On the other-hand, blood transfusion replaces lost blood and supports clotting factor restoration. Factor replacement therapy, desmopressin, clot-preserving medications, gene therapy, and non-factor therapies tailor treatment based on disorder type and severity.
Coagulation Disorders Market- Geographical Insights
The coagulation disorders market shows distinct geographical trends shaped by healthcare infrastructure, disease prevalence, and regional investments. North America dominates the market, owing to high prevalence rates of coagulation disorders, well-established healthcare systems, and robust research and development activities. Additionally, increasing investments in plasma collection centers further boost market growth. Europe holds the second-largest share, with countries like Germany, the UK, France, Italy, and Spain contributing significantly. The region experiences growth through extensive research collaborations, regulatory approvals, and high patient awareness. Aging populations and advancements in diagnostic capabilities contribute to rising demand for coagulation disorder management. The Asia-Pacific region is the fastest-growing, fueled by rising healthcare expenditures, rapid urbanization, and expanding healthcare infrastructure in China, India, and Japan. Due to restricted access to and awareness of healthcare, regions including the Middle East, Africa, and Latin America exhibit slower growth. However, they also exhibit tremendous potential as a result of ongoing healthcare advancements and international collaborations.
Coagulation Disorders Market- Competitive Landscape:
The coagulation disorders market competitive landscape is characterized by the presence of several key global players who are driving innovation through advanced therapies and diagnostic solutions. The key market players focus on developing innovative treatment options such as gene therapies, long-acting recombinant clotting factors, monoclonal antibodies, and biosimilars to improve patient outcomes and quality of life. For instance, in April 2024, Haemonetics Corporation, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TEG 6s hemostasis analyzer system's Global Hemostasis-HN assay cartridge. This new cartridge expanded the TEG 6s system's viscoelastic testing capabilities to include fully heparinized patients undergoing adult cardiovascular surgeries and liver transplantation. Additionally, the adoption of plasma-free recombinant products and advancements in gene editing technologies like CRISPR are key trends shaping competition. Companies are also investing in point-of-care diagnostic tools and wearable coagulation monitoring devices, fostering a shift towards personalized and convenient patient care. Strategic collaborations, mergers, and acquisitions are common as companies strive to expand their product portfolios and regional presence.
Recent Developments:
In July 2025, Bio-Rad Laboratories, Inc. declared the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include Bio-Rad's QX Continuum droplet digital PCR (ddPCR) system, designed for translational research applications with a simplified, qPCR-like workflow, four-color multiplexing, and up to eight discrete thermal profiles per plate. With this launch, Bio-Rad's expanded portfolio of instruments, reagents, software, and services broadens its footprint in genomics research and applied science markets
In September 2025, VarmX B.V. is collaborated with CSL for the development of VMX-C001, a treatment restoring coagulation in patients on FXa DOACs. This treatment is intended to be administered as a single-dose infusion in emergency settings, such as severe bleeding or urgent surgery, where quick restoration of clotting is critical.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL COAGULATION DISORDERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Griflos S.A
- Hoffman-La Roche Ltd
- Bio-Rad Laboratories
- B Braun
- Abbott
- Bayer AG
- Helena Laboratories
- Fresenius Kabi
- Haemonetics Corporation
- VarmX B.V.
- Biogen Inc.
- Others
GLOBAL COAGULATION DISORDERS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032
- Hemophilia A
- Hemophilia B
- Von Willebrand's Disease
- Factor II, V, X, XII Deficiencies
- Others
GLOBAL COAGULATION DISORDERS MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032
- Iron Supplementation
- Blood Transfusion
- Others
GLOBAL COAGULATION DISORDERS MARKET, BY TEST- MARKET ANALYSIS, 2019 - 2032
- Complete Blood Count (CBC)
- Platelet Aggregation Test
- Fibrinogen Assay
- Prothrombin Time Test
- Others
GLOBAL COAGULATION DISORDERS MARKET, BY END USERS- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Blood Banks
- Others
GLOBAL COAGULATION DISORDERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Coagulation Disorders Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Coagulation Disorders Market Snippet by Type
- 2.1.2. Coagulation Disorders Market Snippet by Treatment
- 2.1.3. Coagulation Disorders Market Snippet by Test
- 2.1.4. Coagulation Disorders Market Snippet by End Users
- 2.1.5. Coagulation Disorders Market Snippet by Country
- 2.1.6. Coagulation Disorders Market Snippet by Region
- 2.2. Competitive Insights
3. Coagulation Disorders Key Market Trends
- 3.1. Coagulation Disorders Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Coagulation Disorders Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Coagulation Disorders Market Opportunities
- 3.4. Coagulation Disorders Market Future Trends
4. Coagulation Disorders Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Coagulation Disorders Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Coagulation Disorders Market Landscape
- 6.1. Coagulation Disorders Market Share Analysis, 2024
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Coagulation Disorders Market - By Type
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
- 7.1.2. Hemophilia A
- 7.1.3. Hemophilia B
- 7.1.4. Von Willebrand's Disease
- 7.1.5. Factor II, V, X, XII Deficiencies
- 7.1.6. Others
8. Coagulation Disorders Market - By Treatment
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
- 8.1.2. Iron Supplementation
- 8.1.3. Blood Transfusion
- 8.1.4. Others
9. Coagulation Disorders Market - By Test
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Test, 2024 & 2032 (%)
- 9.1.2. Complete Blood Count (CBC)
- 9.1.3. Platelet Aggregation Test
- 9.1.4. Fibrinogen Assay
- 9.1.5. Prothrombin Time Test
- 9.1.6. Others
10. Coagulation Disorders Market - By End Users
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By End Users, 2024 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Specialty Clinics
- 10.1.4. Diagnostic Centers
- 10.1.5. Blood Banks
- 10.1.6. Others
11. Coagulation Disorders Market- By Geography
- 11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
- 11.2. North America
- 11.2.1. Overview
- 11.2.2. Coagulation Disorders Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
- 11.2.8.1. Overview
- 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.2.8.5. U.S. Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.2.8.6. U.S. Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
- 11.2.9.1. Overview
- 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.2.9.5. Canada Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.2.9.6. Canada Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3. Europe
- 11.3.1. Overview
- 11.3.2. Coagulation Disorders Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
- 11.3.8.1. Overview
- 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.8.5. Germany Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.8.6. Germany Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.9. UK
- 11.3.9.1. Overview
- 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.9.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.9.4. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.9.5. UK Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.9.6. UK Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.10. France
- 11.3.10.1. Overview
- 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.10.5. France Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.10.6. France Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
- 11.3.11.1. Overview
- 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.11.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.11.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.11.5. Italy Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.11.6. Italy Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
- 11.3.12.1. Overview
- 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.12.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.12.4. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.12.5. Spain Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.12.6. Spain Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
- 11.3.13.1. Overview
- 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.13.4. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.13.5. The Netherlands Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.13.6. The Netherlands Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
- 11.3.14.1. Overview
- 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.14.4. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.14.5. Sweden Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.14.6. Sweden Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
- 11.3.15.1. Overview
- 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.15.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.15.4. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.15.5. Russia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.15.6. Russia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
- 11.3.16.1. Overview
- 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.16.4. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.16.5. Poland Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.16.6. Poland Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
- 11.3.17.1. Overview
- 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.17.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.17.5. Rest of the Europe Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.3.17.6. Rest of the Europe Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Coagulation Disorders Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4.8. China
- 11.4.8.1. Overview
- 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.8.5. China Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.8.6. China Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4.9. India
- 11.4.9.1. Overview
- 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.9.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.9.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.9.5. India Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.9.6. India Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
- 11.4.10.1. Overview
- 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.10.5. Japan Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.10.6. Japan Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
- 11.4.11.1. Overview
- 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.11.5. South Korea Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.11.6. South Korea Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
- 11.4.12.1. Overview
- 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.12.5. Australia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.12.6. Australia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
- 11.4.13.1. Overview
- 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.13.5. Indonesia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.13.6. Indonesia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
- 11.4.14.1. Overview
- 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.14.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.14.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.14.5. Thailand Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.14.6. Thailand Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
- 11.4.15.1. Overview
- 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.15.5. Philippines Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.15.6. Philippines Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
- 11.4.16.1. Overview
- 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.16.5. Rest of APAC Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.4.16.6. Rest of APAC Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Coagulation Disorders Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
- 11.5.8.1. Overview
- 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.8.5. Brazil Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.5.8.6. Brazil Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
- 11.5.9.1. Overview
- 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.9.5. Mexico Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.5.9.6. Mexico Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
- 11.5.10.1. Overview
- 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.10.5. Argentina Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.5.10.6. Argentina Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
- 11.5.11.1. Overview
- 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.11.5. Colombia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.5.11.6. Colombia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
- 11.5.12.1. Overview
- 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.12.5. Rest of LATAM Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.5.12.6. Rest of LATAM Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Coagulation Disorders Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
- 11.6.8.1. Overview
- 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.8.5. Saudi Arabia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.6.8.6. Saudi Arabia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
- 11.6.9.1. Overview
- 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.9.5. United Arab Emirates Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.6.9.6. United Arab Emirates Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
- 11.6.10.1. Overview
- 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.10.5. Israel Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.6.10.6. Israel Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
- 11.6.11.1. Overview
- 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.11.5. Turkey Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.6.11.6. Turkey Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
- 11.6.12.1. Overview
- 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.12.5. Algeria Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.6.12.6. Algeria Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
- 11.6.13.1. Overview
- 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.13.5. Egypt Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.6.13.6. Egypt Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
- 11.6.14.1. Overview
- 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.14.5. Rest of MEA Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
- 11.6.14.6. Rest of MEA Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Coagulation Disorders Industry
- 12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
- 12.2. Company Profiles
- 12.2.1. Griflos S.A
- 12.2.2. Hoffman-La Roche Ltd
- 12.2.3. Bio-Rad Laboratories
- 12.2.4. B Braun
- 12.2.5. Abbott
- 12.2.6. Bayer AG
- 12.2.7. Helena Laboratories
- 12.2.8. Fresenius Kabi
- 12.2.9. Haemonetics Corporation
- 12.2.10. VarmX B.V.
- 12.2.11. Biogen Inc.
- 12.2.12. Others
13. 360 Degree AnalystView
14. Appendix
- 14.1. Research Methodology
- 14.2. References
- 14.3. Abbreviations
- 14.4. Disclaimer
- 14.5. Contact Us
